Inflammation

1.0 Credit / Immunology, Neurology

Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis

1 Credit / Cardiology, Neurology

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

August 13, 2025 | 1:00 PM & 8:00 PM EDT

From Treatment to Prevention: Navigating the Expanding Hereditary Angioedema Treatment Landscape

August 19, 2025 | 1:00 PM & 8:00 PM ET

Innovations in Hidradenitis Suppurativa Treatment: Navigating the Evolving Landscape for Managed Care Professionals

August 21, 2025 | 1:00 PM ET & 8:00 PM ET

Optimizing Outcomes in Myasthenia Gravis: Therapeutic Advances and Value-Based Care Models

1.0 Credit / Gastroenterology, Immunology, Rare Diseases

Managed Care Insights on the Advances in the Eosinophilic Esophagitis Treatment Landscape

1.0 Credit / Immunology, Pulmonology/Respiratory

Managing Patients With COPD: Evidence-Based Care and Optimizing Value of New and Emerging Targeted Therapies

Managed Care Approaches to Individualize Treatment of Hereditary Angioedema

1.0 Credit / Immunology

1.5 Credits / Allergy, Immunology

From Strict Avoidance to Tailored Therapies: Transforming Food Allergy Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Immunology, Allergy

Leveraging Biologics and Immunotherapies in the Management of Food Allergies

1.5 Credits / Immunology, Pulmonology

Reflecting on the Real-World Use of Biologic Therapy in Asthma Management

Targeting Chronic Rhinosinusitis With Nasal Polyps With Biologics: Optimizing Outcomes and Reducing Health Care Burden

1.5 Credits / Immunology

1.5 Credits / Gastroenterology, Immunology

Emerging Treatment Options for Inflammatory Bowel Disease: A Focus on IL-23 Pathway Inhibition

1.5 Credits / Gastroenterology, Immunology

Innovations in Inflammatory Bowel Disease Therapy: How IL-23 Inhibitors Are Shaping Treatment and Managed Care Approaches

1.0 Credit / Immunology, Nephrology

The Expanding Therapeutic Landscape in IgA Nephropathy: Applying Evidence-Based Strategies and Guideline Updates for Managed Care

1.0 Credit / Immunology, Nephrology

The Expanding Therapeutic Landscape in IgA Nephropathy: A Case-Based Exploration of Optimized Patient Outcomes

More News

June 8th 2022

Dupilumab Efficacy in Asthma, AD, EoE, and CRSwNP Not Affected By Eosinophil Count

Dupilumab-induced increases in mean eosinophil counts were shown to wane over time in patients with asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and atopic dermatitis (AD), with incidence of eosinophilia not shown to reduce efficacy of the biologic.

June 4th 2022

Study Identifies Predictors of Eosinophilic Disease in CRS With Nasal Polyps

Asthma history and olfactory, rhinorrhea, and nasal polyp endoscopy scores were identified as independent predictors of eosinophilic disease in Chinese patients with chronic rhinosinusitis with nasal polyps.

June 3rd 2022

Long-term Use of Budesonide Nasal Irrigation Effective for Comorbid CRS With Nasal Polyps, Asthma

Patients with comorbid chronic rhinosinusitis (CRS) with nasal polyps and asthma reported significant reductions in endoscopic sinus score and severity, as well as decreased dosage of oral steroids and antibiotics after long-term use of budesonide nasal irrigation.

May 31st 2022

Review of Current EoE Treatment Landscape Highlights Several Promising Agents

Rose McNulty

A recent review points to a host of potentially disease-modifying agents currently in clinical trials.

May 27th 2022

Assessing Comorbidities in Eosinophilic Esophagitis

Gianna Melillo

Investigators in Spain evaluated symptoms and comorbidities associated with eosinophilic esophagitis.

May 22nd 2022

Dupilumab Reduces OCS Dosage, Improves Lung Function for Asthma, CRSwNP

Dupilumab was associated with reductions in exacerbations and oral corticosteroids (OCS) dosage, as well as improved lung function, in patients with OCS-dependent asthma with and without comorbid chronic rhinosinusitis with nasal polyps.

May 20th 2022

FDA Approves Dupilumab as First Therapy for Eosinophilic Esophagitis

Eosinophilic esophagitis is a chronic inflammatory disorder in which eosinophils, a type of white blood cell, proliferate in the esophagus, causing difficulties with eating and swallowing.

May 20th 2022

Chitosan-Based Gel Found to Lower Risk of Wound Infection, Synechia After Nasal Polyps Surgery

Use of a chitosan-based gel dressing after endoscopic sinus surgery for nasal polyps was found to reduce risk of wound infection and synechia in patients, although no difference was observed regarding granulations.

May 16th 2022

Dupilumab Improves Lung Function, Asthma Attacks in Children With Atopic Comorbidities

Dupilumab improved lung function and reduced severe asthma exacerbation rates in children with moderate to severe asthma with or without atopic comorbidities.

May 15th 2022

Rare, Novel Chromosomal Duplication of Entire IL-33 Gene Documented in Case Study

Jaime Rosenberg

In their paper, the researchers detail the first, to their knowledge, case of a potential gain of function phenotype for IL-33 in a human.

May 13th 2022

Colette Romero on the Strategies Her Family Uses to Cope With EoE

Colette Romero, whose child has eosinophilic esophagitis (EoE), describes some of the coping strategies her family uses to encourage her son to keep healthy.

May 12th 2022

Improved Sense of Smell Achieved With Biologics for CRS With Nasal Polyps, Asthma

Patients with comorbid chronic rhinosinusitis (CRS) with nasal polyps and severe asthma reported significant improvement in their sense of smell when treated with the biologics omalizumab, mepolizumab, reslizumab, or benralizumab, with no significant differences observed between the treatment groups.

May 9th 2022

EoE Research Examines Long-term Efficacy of PPIs in Responders

A recent study sought to address what is known about proton pump inhibitors (PPIs) as a therapy for eosinophilic esophagitis and long-term outcomes in patients who respond to them as a way to guide treatment decisions.

May 9th 2022

Experts Provide Overview of CRSwNP, Available Biologic Treatments

Gianna Melillo

Katharine Rimes, PharmD, and John Bosso, MD, discussed updates in management of chronic rhinosinusitis with nasal polyps at the 2022 Asembia Specialty Pharmacy Summit.

May 5th 2022

Machine Learning Identifies Predictors of Revision Endoscopic Sinus Surgery

A machine learning approach identified age and several comorbidities, such as nasal polyps and asthma, as being associated with revision endoscopic sinus surgery among patients with chronic rhinosinusitis.

May 4th 2022

Report Describes Case of Eosinophilic Enteritis Complicated by CMV

The authors said that to their knowledge, this is the first report of cytomegalovirus (CMV) that developed during the treatment of eosinophilic enteritis in an adult.

May 3rd 2022

Clinical Improvement of AERD Achieved With Dupilumab Use for Asthma, CRS With Nasal Polyps

Patients with aspirin-exacerbated respiratory disease (AERD) who initiated treatment with dupilumab as an add-on asthma or chronic rhinosinusitis with nasal polyps therapy reported rapid clinical improvement that was sustained after 3 months.

April 30th 2022

HPV Infection May Increase Risk of Developing CRS With Nasal Polyps

Presence of human papillomavirus (HPV) was significantly associated with incidence of chronic rhinosinusitis with nasal polyps (CRSwNP), although no differences in disease severity were observed among HPV-positive and HPV-negative patients with CRSwNP.

April 29th 2022

Proton Pump Inhibitors Plus Food Elimination Diet Superior to Monotherapy in Refractory EoE

A small retrospective study examined outcomes in patients with eosinophilic esophagitis (EoE) who did respond to solo therapies.

April 28th 2022

Real-world Patients Show Significant Improvement With Dupilumab for CRS With Nasal Polyps

Use of dupilumab was associated with significant improvement in clinical symptoms of chronic rhinosinusitis (CRS) with nasal polyps among real-world patients in Canada, with benefits shown to be similar to that observed in randomized clinical trials.

April 23rd 2022

Surveyed Patients Identify Unmet Needs in CRS With Nasal Polyps

Patients with chronic rhinosinusitis (CRS) with nasal polyps identified several unmet needs regarding their condition, particularly a lack of public and physician awareness on disease burden and poor sleep quality.

April 21st 2022

Novel Fluticasone Delivery System Found to Reduce Nasal Polyps Severity

An exhalation system with fluticasone was shown to significantly reduce nasal polyp score at 4 and 16 weeks compared with placebo, with improvements also observed in several patient-reported outcomes.

esophagus highlighted through woman touching her throat

April 19th 2022

Patients With EoE Lack Effective, Targeted Therapies for Long-term Disease Control, Review Finds

Laura Joszt, MA

The lack of effective long-term control of eosinophilic esophagitis (EoE) highlights the unmet need for targeted systemic therapies.

April 16th 2022

Psychiatric Disease Risk Higher for Patients With EoE, Study Says

Other gastrointestinal disorders and inflammatory diseases have also been linked to psychiatric disorders, but not much is known about the connection to eosinophilic esophagitis (EoE).

April 15th 2022

In Adults With EoE, Dilation May Mask Underlying Inflammation

The study was conducted because information on the relationship between eosinophilic esophagitis (EOE) symptoms and biologic findings are limited, so researchers looked at the long-term effects of esophageal dilation, including patient-reported outcome (PRO) measures.

April 13th 2022

CRS With Nasal Polyps Linked With Reduced Health-Related QOL Across Patient Subgroups

Reduced health-related quality of life was identified in patients with chronic rhinosinusitis with nasal polyps compared with the general population—regardless of previous sinus surgery or presence of comorbidities.

April 11th 2022

Dupilumab Creates Rapid, Sustained Responses in Asthma, CRSwNP, and AD

Laura Joszt, MA

Across 3 disease states, dupilumab has been shown to create rapid, clinically meaningful responses that were sustained, which could improve adherence and the patient-provider relationship.

April 9th 2022

Biomarker Identifies CRSwNP Endotypes, Risk of Postoperative Nasal Polyp Recurrence

Circulating B cell–activating factor was shown to be a potential biomarker in identifying blood eosinophil counts and risk of postoperative nasal polyp recurrence among patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

April 8th 2022

Older EoE Patients More Likely to Respond to Topical Corticosteroids, Study Finds

Julia Bonavitacola

Recent clinical trials have excluded older patients with eosinophilic esophagitis (EoE) from participating; however, patients aged 65 years and older are more likely to respond to topical corticosteroids than their younger counterparts.

April 7th 2022

Postoperative Recurrence Risk of Nasal Polyps Greater in Young Men